17 Years at AB|18 Years of Experience
Edward Bryan is a Portfolio Manager for the Sustainable Global Small Cap Portfolio, and Senior Research Analyst for the Sustainable Thematic Equities team, responsible for covering the global healthcare sector. He began his career at AB in 2007 as an associate in the Institutional Investments division. In 2010, Bryan became a trading desk analyst in the US Equities Trading department. He joined the research team in 2011. Bryan holds a BA in economics from Franklin & Marshall College and is a CFA charterholder. Location: New York
Despite conventional wisdom, political uncertainty doesn’t necessarily pose acute risks to the healthcare sector.
Vinay Thapar, Edward Bryan | 27 February 2024Technology and creative research should continue to drive company breakthroughs in medicine and packaging.
Edward Bryan, Vinay Thapar | 01 November 2022ESG ratings are lacking for small-cap stocks globally. This prevents asset managers that rely on third-party ratings from building small-cap funds.
Edward Bryan, Dan Roarty | 25 August 2022Can solutions to supply chain disruptions be found in a fermentation tank? The crisis could accelerate the adoption of synthetic biology to ensure sustainable supply of many products.
Edward Bryan | 08 April 2022Synthetic biology is not science fiction. Investors should get acquainted with a technology that will create sustainable solutions in many industries.
Sarah Tunnell, Edward Bryan | 13 January 2022As the transformational science of synthetic biology makes a growing impact on more industries, equity investors will find exciting opportunities.
Edward Bryan | 23 November 2021Diagnostics - the back-end robotics in the health care system - are helping automate many complex procedures. Diagnostics are not only increasingly aiding the treatment of patients with infectious diseases but accelerating the broader trend toward personalized health care.
Dan Roarty, Edward Bryan | 24 August 2020This information is for exclusive use of the wholesale person to whom it is provided and is not to be relied upon by any other person. It is not intended for retail or public use and may not be further distributed without prior written consent of ABAL.
This webpage has been prepared by AllianceBernstein Australia Limited (“ABAL”)—ABN 53 095 022 718, AFSL 230 698. Information in this webpage is only intended for persons that qualify as “wholesale clients,” as defined by the Corporations Act 2001, and is not to be construed as advice. This webpage is provided solely for informational purposes and is not an offer to buy or sell securities. The information, forecasts and opinions set forth in this webpage have not been prepared for any recipient’s specific investment objectives, financial situation or particular needs. Neither this webpage nor the information contained in it are intended to take the place of professional advice.
You should not take action on specific issues based on the information contained in this webpage without first obtaining professional advice. Past performance does not guarantee future results. Projections, although based on current information, may not be realized. Information, forecasts and opinions can change without notice and ABAL does not guarantee the accuracy of the information at any particular time. Although care has been exercised in compiling the information contained in this webpage, ABAL does not warrant that this webpage is free from errors, inaccuracies or omissions. ABAL disclaims any liability for damage or loss arising from reliance upon any matter contained in this webpage except for statutory liability which cannot be excluded.
No reproduction of the materials on this webpage may be made without the express written permission of ABAL. This information is provided for persons in Australia only and is not being provided for the use of any person who is in any other country.